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Summary: Using an immunoenzymatic method, we studied
lipase in the serum and urine of 23 controls, 22 chronic pan-
creatitis patients in symptomatic remission, and in 9 patients
with proven pancreatic cancer. Serum and urine lipase and its
fractional urinary clearance were compared with those of am-
ylase and immunoreactive trypsin. Lipase immunoreactivity
was detectable in the urine of 81.5% of the studied subjects
(controls: 82%, chronic pancreatitis: 86%, pancreatic cancer:
66%); its output was higher than the upper limit of controls in
31.8% of chronic pancreatitis and in only 1 of pancreatic cancer,
and it was significantly correlated with the urinary output of
trypsin (r = 0.487, P < 0.001), but not with that of amylase.
A significant correlation was found between urinary output and
serum levels for lipase, but not for trypsin or amylase. Frac-
tional clearance of lipase was of the same magnitude as that of
trypsin but only 0.1% that of amylase. 19% of chronic pan-
creatitis and pancreatic cancer showed a fractional clearance
of lipase above the upper limit of controls, compared with 45%
for trypsin and 3.2% for amylase. No difference in urinary
clearance of the three enzymes was found between chronic
pancreatitis and pancreatic cancer. In conclusion, although of
no diagnostic relevance in pain-free patients with chronic pan-
creatic disease, this measurement can provide information on
the mechanisms of renal excretion of pancreatic enzymes.
Introduction
The diagnostic value of the urinary clearance of pancreatic
enzymes1) in acute arid chronic pancreatic diseases is still a
matter of wide debate. Some authors have considered an in-
crease in the urinary clearance of amylase as an index of acute
pancreatitis (1, 2) and others have considered the urinary clear-
ance of trypsin a useful tool in the differential diagnosis between
chronic pancreatitis and pancreatic cancer (3), whereas the
clinical relevance of these assays has been denied by some
authors both for amylase and for trypsin (4—13).
') Amylase; EC 3.2.1.1
Pancreatic lipase: EC 3.1.1.3
Catfoodal trypsin: EC 3.4.21.4
In the past, urine was investigated for lipase activity, using
relatively insensitive methods. It was not detected (14, 15)
because physico-chemical factors influence the urinary activity
(as also found for trypsin (16 — 17)), or possibly due to the
renal handling of the enzyme. Since a new immunoenzymatic
method for lipase measurement is now available (18), the aim
of this study was to investigate the levels of urinary lipase
immunoreactivity, and the urinary clearance of lipase, and to
compare them with amylase and trypsin serum and urine levels.
Patients and Methods
This investigation was carried out on 54 subjects (46 males and
8 females, aged 20—65 years), comprising 23 controls, 22 pa-
tients with uncomplicated chronic pancreatitis (all alcoholic in
origin, pain-free since at least four weeks), and 9 with surgically
and histologically proven pancreatic cancer. Controls were cho-
sen from hospital staff and inpatients not suffering from any
digestive or renal disease. The following exclusion criteria were
followed: presence of urinary infection (colony forming units
> 50 χ 106/l)i renal impairment (blood urea nitrogen > 23
mg/dl; creatinine clearance < 40 ml/min in females, < 60 ml/
min in males; proteinuria > 0.5 g/1); treatment with cytostatic
drugs and/or aminoglycoside antibiotics. Urine was collected
over a 12 hour period from 8 pm to 8 am in a bag containing
4 ml of a 250 g/1 Na azide solution. All blood samples were
taken after an overnight fast, at the end of the urine collection
period, and the serum was stored at —20 °C until assay. Serum
amylase was determined according to Pierre (19); lipase by the
immunoenzymatic method proposed by Grenner et al. (18)
(Enzygnost-Lipase, Behringwerke, Marburg, West Germany),
modified by ourselves (20) (detection limit 0.5 μg/l); trypsin by
the method of Malvano et al. (21) (Trypsik Riakit, Sorin,
Saluggia, Italy). For the urine assay of lipase and trypsin, 60
ml of fresh urine were concentrated 30-fold by uitrafiltration
(Amicon concentrator, Diaflo YM5 membrane; 95% cut off
limit at Mr = 5000). Since the dilution curve of concentrated
urine samples was not parallel to the standard curve of trypsin
in serum, a standard curve was constructed, using the virtually
trypsin-free urine of a patient with chronic pancreatitis, A
detection limit as low as 0.1 Mg/1 with a recovery of 103 + 3.6%
(x + 1 SD) was obtained with a four-fold dilution of the re-
agents and a 48 hour incubation period at 4 °C.
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For urine lipase the serum method was used without modifi- Amylase Trypsin Lipase
cation. Serum and urine creatinine was measured by means of 10000-
an automated reaction-rate- method (22). The fractional clear- '
ance of the three enzymes (i. e., the ratio between their urinary ^
clearance and that of creatinine) was evaluated according to 2
Levin et al. (1). The linear correlation index "r" was calculated 5
after logarithmic transformation of the data. 2
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Results ο
A urine lipase recovery ranging from 84 to 94% for increasing ;>
enzyme concentrations was found. When the same urine of 5 g
patients was concentrated on two different days a coefficient
 α 100_
of variation ranging from 1.28 to 10.86% was found. Virtually '^
no difference in the lipase and trypsin values was observed 2
when the concentration was decreased stepwise from 30 to 5 υ
fold, or after adding, to two concentrated urine samples, bovine ζ
serum albumin up to 200 g/1 (to rule out concentration artifacts .E
in patients with proteinuria). 3 10-
Figure 1 shows the distribution of the individual values of the 5 'jj[
enzymes in serum. In chronic pancreatitis patients 22.7%, !*£
13.6% and 45.4% of serum amylase, trypsin and lipase values <
respectively were above the upper limit found in our 23 controls,
and 0%, 27.2% and 18.1% respectively were below the lower
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limit of controls. Figure 2 shows the distribution of enzyme C CP PC C CP PC C CP PC
levels in urine. A similar percentage of chronic pancreatitis
patients (31.2 to 45.8%) showed a high urine output of each Fig· 2. Urinary outputs of the studied enzymes (on log scale).
enzyme. A significant linear correlation was found between Legends as in figure 1 .
urine output and serum level for lipase (r = 0.504; ρ < 0.001)
but not for trypsin or amylase. A significant, even if weak,
correlation (r = 0.487; ρ < 0.001) was found only between the
urinary output of trypsin and of lipase. Figure 3 shows the Amylase Trypsin Lipase
fractional clearance of amylase, of trypsin and of lipase. Lipase g Q -
fractional clearance was very low, of the same magnitude as c
trypsin and roughly a thousand times less than amylase. Only £
19% of chronic pancreatitis and of pancreatic cancer patients £
showed a lipase fractional clearance above the upper limit of ^
our controls, compared with 45% for trypsin and 3.2% for .-tT
amylase. «
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Discussion
η ι
C CP PC C CP PC C CP PC
Fig. 1. Serum levels of the studied enzymes (on log scale) in
controls (C) and in patients with chronic pancreatitis
(CP) and with pancreatic cancer (PC).
By employing a new immunoenzymatic method for lipase (18)
in 30-fold concentrated urines, we were able to measure a
significant urinary output in 81.5% of the studied subjects. Very
low urinary levels of this enzyme (especially if compared with
amylase) were however found in the majority of our patients.
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It is generally assumed that this small protein is filtered by
renal glomeruli. Therefore a substantial tubular reabsorption
is to be expected (23), as shown for amylase in the proximal
tubule (10, 24, 25), and as concluded for Upase in man (26) on
the basis of an increased urinary lipase output after selective
tubular block by lysine intravenous infusion. The tubular reab-
sorption of lipase seems to be far more efficient than that of
amylase and of the same order of magnitude as that of trypsin.
On the other hand, lipase and trypsin seem to show different
excretory behaviour, since a linear correlation between serum
level and urinary output is found for the former and not for
the latter enzyme. Abnormal values of trypsin fractional clear-
ance are found in 45% of patients with chronic pancreatic
diseases, possibly due to some form of subclinical tubular
derangement (27) fairly specific for trypsin. since for lipase it
occurs only in 19 percent of patients.
In conclusion, even if no clinical value can be attributed to the
lipase urinary excretion in pain-free patients with chronic pan-
creatic diseases, this measurement can provide information of
pathophysiological relevance to renal derangement in these
diseases.
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